Faron strengthens executive team by appointing new Medical Director

He will play a central role in expanding the Finnish firm's clinical programmes of drug candidates

Matti Karvonen is the new Medical Director at Faron Pharmaceuticals, a Finnish developer of treatments for medical conditions with significant unmet needs. Karvonen will oversee Faron´s drug development strategy and will play a central role in expanding the clinical programmes of drug candidates Traumakine, for treating acute respiratory distress syndrome and potential immuno-oncology drug Clevegen.

Karvonen has a background in clinical neurology with medical experience in many international pharmaceutical organisations, including Roche, Biogen Idec and Novartis. He has also participated in many clinical programmes, most recently in the pan-European launch of a new neurological drug. In the early part of his career Karvonen held several research positions and he has also co-founded several commercial medical organisations.

Companies